Publications

Show details

The pharmaceutical industry has grown in recent years to become one of the most important pillars in various regions of Switzerland, if not the crucial driver of the regional economy. This study by BAK Economics AG illustrates the various impact channels as exemplified by the biotechnology company Biogen, which is investing around CHF 1.5 billion in the construction of a next-generation biopharmaceutical production facility in Luterbach. This production facility in the canton of Solothurn will directly create some 600 new jobs. Aside from the 400 jobs in biopharmaceutical production, a further 200 will be created in the outsourced areas of building maintenance, cleaning and catering. On the basis of model calculations, BAK reckons that the Biogen plant will result in an additional growth potential of 1.5 to 2.0 percent of the cantonal gross domestic product in 2019, and that the Biogen investment will generate a gross value added of more than CHF 800 million in the whole of Switzerland.

Show details

The most important facts and figures on Switzerland’s healthcare and pharma landscape

Show details

Vision for Switzerland as a pharma hub in 2030: «Switzerland is still Europe's leading pharma hub in 2030. It benefits from high-quality medical innovation and is able to fund this innovation in the long run and sustainably. The pharmaceutical industry is a key contributor to the prosperity and quality of life of people in Switzerland.»

Show details

Show details

The annual report provides information on Interpharma's priorities and activities as well as key figures and information about the research-based pharmaceutical industry. The texts are accompanied by illustrations and graphics. The report contains the major regional and national key figures for the pharmaceutical industry, including gross value added, headcount, productivity, exports and R&D expenditures. It also describes the major communication projects and political topics.